Evidence map›Paper›PMID 30931453›Full record

ArticleChemical communications (Cambridge, England)2019

A novel fluorescent surfactant enhances the delivery of the Cas9 ribonucleoprotein and enables the identification of edited cells.

Jie Li, Joachim Justad Røise, Jingtuo Zhang, Jiaying Yang, D Lucas Kerr, Hesong Han, Niren Murthy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical communications (Cambridge, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jie LiDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA 94720, USA. nmurthy@berkeley.edu.
Joachim Justad Røise
Jingtuo Zhang
Jiaying Yang
D Lucas Kerr
Hesong Han
Niren Murthy

Funding

Consortium for drug-resistant Gram-negative pathogen detectionR01AI117064 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI LEE, LUKE P., MURTHY, NIREN · 2015 to 2019
$5.7M
18F Conjugated Maltodextrins for the Detection of Medical Device InfectionsR01EB020008 · NIBIB · EMORY UNIVERSITY · PI GOODMAN, MARK MYRON, MURTHY, NIREN · 2015 to 2018
$2.4M
Treatment of Duchenne Muscular Dystrophy with Cas9 Protein Complexed to Gold NanoparticlesR01EB023776 · NIBIB · UNIVERSITY OF CALIFORNIA BERKELEY · PI CONBOY, IRINA M, MURTHY, NIREN · 2017 to 2020
$1.4M
Maltose Targeted AntibioticsR33AI119115 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI MURTHY, NIREN, RILEY, LEE W · 2017 to 2019
$1.4M
NIAID NIH HHS R01 AI117064NIAID NIH HHS R33 AI119115NIBIB NIH HHS R01 EB020008NIBIB NIH HHS R01 EB023776
6 · The paper itself

Abstract

In this report, we designed and synthesized a novel fluorescent single tailed surfactant (termed FEDS), which can disrupt endosomes, complex lipofectamine, and can also identify cells that have been transfected. FEDS was able to increase the gene editing efficiency of lipofectamine/Cas9 ribonucleoprotein by 300% via a combination of fluorescent based enrichment and endosomal disruption.

Indexed as

AnimalsCell LineCRISPR-Associated Protein 9EndosomesErythrocytesFlow CytometryFluorescent DyesGene EditingGreen Fluorescent ProteinsHumansLipidsRabbitsCRISPR-Associated Protein 9Fluorescent DyesGreen Fluorescent ProteinsLipidsLipofectamine

Identifiers

PMID30931453
PMCPMC6503854

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.